MedTrace Logo

Observational Study in Patients With Nail Psoriasis Treated With Enstilar® to Assess the Severity Change and the Quality of Life

NCT04380597 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2021-08-02

No results posted yet for this study

Summary

Observational, prospective and multicentre study to evaluate the effectiveness of calcipotriene and betamethasone dipropionate aerosol foam (Cal / BD), prescribed according to clinical practice and following the Product Data Sheet instructions, in the topical treatment of nail psoriasis according to the change in the score of the Nail Psoriasis Severity Index (NAPSI) at 12 weeks of treatment with respect to the initial score.

Conditions

  • Nail Psoriasis

Interventions

DRUG

Calcipotriene and betamethasone dipropionate aerosol foam

Prescribed according to clinical practice and following Product Data Sheet instructions

Sponsors & Collaborators

  • Angeles Florez

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-26
Primary Completion
2019-12-15
Completion
2021-07-30
FDA Drug
Yes

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04380597 on ClinicalTrials.gov